ArticleInternational urology and nephrology2015
Patient preferences for treating refractory overactive bladder in the UK.
Article in International urology and nephrology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05519072 (Use of Prophylactic Antibiotics Prior to OnabotulinumtoxinA Treatment of Overactive Bladder), which is not on this map. Cited by 18 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Use of Prophylactic Antibiotics Prior to OnabotulinumtoxinA Treatment of Overactive Bladder: a Randomized Controlled Trial
Who cites it
18 citing papers in PubMed, 1 synthesis or guideline pooled it, 34 citations in OpenAlex.
- Using Best-Worst Scaling to Investigate Preferences in Health Care.PharmacoEconomics · 2016Pooled it
- Onabotulinum Toxin A-Led Urinary Tract Infections-Should we Safeguard? A Randomized Controlled Trial.International urogynecology journal · 2025Trial
- Which antimuscarinic agents used in the treatment of overactive bladder increase heart rate? a prospective randomized clinical trial.International urology and nephrology · 2019Trial
- Do We Have Sufficient Evidence to Derive Innovative Approaches to Assessing Unmet Need, Delivering Education on Bladder and Bowel Continence Health, and Providing a Better Environment for Joint Decision-Making? ICI-RS 2024.Neurourology and urodynamics · 2025Article
- Time-dependent, patient-centered perceptions of quality measures for total joint arthroplasty: a cross-sectional, choice modeling study.BMC musculoskeletal disorders · 2025Article
- Awareness and barriers of sacral neuromodulation in women with overactive bladder.Archives of gynecology and obstetrics · 2024Article
- Patients' Preferences and Expectations in Overactive Bladder: A Systematic Review.Journal of clinical medicine · 2023Review
- Adherence to Overactive Bladder Syndrome Treatments Recent Developments and Future Perspectives.International journal of women's health · 2023Review
- Barriers and facilitators to overactive bladder therapy adherence.Neurourology and urodynamics · 2022Review
- Delivering patient-centered care through shared decision making in overactive bladder.Neurourology and urodynamics · 2022Review
- Assessment of Anticholinergic Use After Fading of BTX-A Effects in Refractory Idiopathic Overactive Bladder: A Prospective Blinded Randomized Trial.International neurourology journal · 2019Article
- Initial clinical experience with selective bladder denervation for refractory overactive bladder.Neurourology and urodynamics · 2019Article
- [Sacral neuromodulation for refractory overactive bladder].Der Urologe. Ausg. A · 2018Article
- Transcutaneous tibial nerve stimulation: 2 years follow-up outcomes in the management of anticholinergic refractory overactive bladder.World journal of urology · 2018Observational
- Urinary retention in female OAB after intravesical Botox injection: who is really at risk?International urogynecology journal · 2017Article
- Effectiveness of percutaneous tibial nerve stimulation in the treatment of overactive bladder syndrome.Research and reports in urology · 2017Review
- Experimental measurement of preferences in health and healthcare using best-worst scaling: an overview.Health economics review · 2016Article
- Overactive bladder.F1000Research · 2015Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 5 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo evaluate patient preferences for refractory overactive bladder (OAB) treatments: sacral neuromodulation (SNM), onabotulinum toxin A (Botox(®)), and percutaneous tibial nerve stimulation (PTNS). MATERIALS AND
methodsA cross-sectional Web survey was conducted with UK idiopathic OAB patients, recruited by a market research company. Preference was explored using direct questioning, comparing SNM, Botox, and PTNS, and via best-worst scaling (BWS). In BWS, patients prioritized subsets of 13 treatment characteristics (attributes) across 13 choice tasks, identifying the attribute they considered best and worst in each task. The attributes were those that were identified by patients in previous qualitative interviews as influential in treatment selection. BWS scores for each attribute, ranging from 1.0 (most favourable) to -1.0 (most unfavourable), were calculated based on the rates they were identified as best and as worst. To identify attributes that may influence treatment choice, BWS scores were compared among patients based on their most preferred treatment using analyses of variance; pairwise differences were assessed using Tukey's multiple comparisons test.
resultsThe study population (N = 139) was 77 % female, had a mean age of 49 years, and were diagnosed a mean of 6.1 years ago. All 13 attribute BWS scores were viewed positively (score > 0.0) or negatively (score < 0.0). Among the 127 (91 %) of patients who had experience with OAB medication only, most (≥80 %) were willing to try each of the three treatments; 57, 34, and 9 % most preferred PTNS, SNM, and Botox, respectively. Preferences for the attributes differed based on which treatment that patients preferred. Specifically, patients preferring SNM (PS) favoured 'implanted device in upper buttock' more than those preferring PTNS (PP) or Botox (PB). Compared to PB, PS also favoured 'sends signals between bladder and brain to help restore bladder function' and 'test phase'. PB favoured 'Botox (botulinum toxin) treatment' and 'treatment procedure delivered through the urethra' more than PS and PP. PP favoured the following more than PS and PB: 'needle inserted into ankle', 'minimal side effects' and 'treatment requires repeated visits over time'.
conclusionThis study identified specific characteristics of specialized therapies for refractory OAB that may significantly influence patient preferences, which may be used to help inform treatment decision-making.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.